Alcon, the eye care business of Novartis, has announced plans to locate its future global headquarters in Geneva once its proposed spinoff from Novartis International is complete. The Swiss group decided to cut ties with Alcon in July, to focus on its portfolio of pharmaceutical products (see Eyewear Intelligence, Vol. 19, no. 10-11). The transaction will remain pending until the annual general meeting in February 2019, when the company will seek shareholder approval. Novartis said the planned spinoff would create the world's leading eye-care device company, with more than 20,000 employees and annual sales of around $7 billion. Alcon's new headquarters will be the primary location for corporate and commercial functions. It will be co-located with the company's EMEA office, already based in Geneva. Alcon's management has said in a press release that being headquartered in Geneva will expand Alcon's global scale and reach to better serve its customers. The new listed holding company for the post-spinoff Alcon group will be incorporated in the Canton of Fribourg, where Alcon already has significant operations. According to Alcon management, the company could then employ up to 700 in Switzerland. The current global divisional headquarters, in Fort Worth, Texas, will remain a major operational, commercial, and innovation hub.